Chicago Partners Investment Group LLC Takes $353,000 Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Chicago Partners Investment Group LLC acquired a new stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 27,200 shares of the biopharmaceutical company's stock, valued at approximately $353,000.

Several other large investors also recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Dynavax Technologies by 0.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,157,993 shares of the biopharmaceutical company's stock worth $15,019,000 after acquiring an additional 2,913 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Dynavax Technologies by 0.5% during the first quarter. Blair William & Co. IL now owns 2,272,707 shares of the biopharmaceutical company's stock worth $29,477,000 after buying an additional 11,030 shares in the last quarter. Natixis Advisors LLC grew its holdings in shares of Dynavax Technologies by 16.8% during the first quarter. Natixis Advisors LLC now owns 26,314 shares of the biopharmaceutical company's stock worth $341,000 after buying an additional 3,778 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Dynavax Technologies by 57.0% during the first quarter. XTX Topco Ltd now owns 76,854 shares of the biopharmaceutical company's stock worth $997,000 after buying an additional 27,893 shares in the last quarter. Finally, Bryce Point Capital LLC bought a new position in shares of Dynavax Technologies during the first quarter worth about $357,000. 96.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. JMP Securities increased their price objective on Dynavax Technologies from $31.00 to $32.00 and gave the stock a "market outperform" rating in a report on Friday, August 8th. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday. Finally, The Goldman Sachs Group decreased their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Stock Up 2.3%

NASDAQ DVAX traded up $0.24 during trading hours on Wednesday, hitting $10.82. 1,911,186 shares of the company traded hands, compared to its average volume of 2,104,242. The business's 50-day moving average is $10.54 and its 200-day moving average is $11.52. Dynavax Technologies Corporation has a twelve month low of $9.22 and a twelve month high of $14.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -23.52 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. The firm had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Sell-side analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.